6 April 2018 - - US-based clinical-stage biotechnology company Vaxart, Inc. has presented the complete clinical dataset from the Phase 2 challenge study of its H1 influenza oral tablet vaccine in an oral presentation at the World Vaccine Congress in Washington, DC, the company said.
The Phase 2 study was completed with support from the Biomedical Advanced Research and Development Authority (BARDA).
Vaxart received a USD 13.9m contract from BARDA in September 2015 to support the advanced development of more effective influenza vaccines to ultimately improve seasonal and pandemic influenza preparedness.
The project has been funded in whole or in part with federal funds from the Department of Health and Human Services' Office of the Assistant secretary for Preparedness and Response; BARDA.
Vaxart is focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform.
The company's oral vaccines are designed to generate broad and durable immune responses that protect against a range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer.
Its development programs include oral tablet vaccines designed to protect against norovirus, seasonal influenza and respiratory syncytial virus, as well as a therapeutic vaccine for human papillomavirus.